MX2021015762A - Composiciones. - Google Patents

Composiciones.

Info

Publication number
MX2021015762A
MX2021015762A MX2021015762A MX2021015762A MX2021015762A MX 2021015762 A MX2021015762 A MX 2021015762A MX 2021015762 A MX2021015762 A MX 2021015762A MX 2021015762 A MX2021015762 A MX 2021015762A MX 2021015762 A MX2021015762 A MX 2021015762A
Authority
MX
Mexico
Prior art keywords
compositions
binding polypeptide
tnf
composition
inter alia
Prior art date
Application number
MX2021015762A
Other languages
English (en)
Inventor
Scott Crowe
Mike West
Kevin Roberts
Tim Carlton
Luana Maggiore
Marion Cubitt
Keith Ray
Lurdes Duarte
Original Assignee
Sorriso Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorriso Pharmaceuticals Inc filed Critical Sorriso Pharmaceuticals Inc
Publication of MX2021015762A publication Critical patent/MX2021015762A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona, entre otras cosas, una composición que comprende un polipéptido de unión a TNF-alfa y un polipéptido de unión a IL-7R.
MX2021015762A 2019-06-21 2020-06-19 Composiciones. MX2021015762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181869 2019-06-21
PCT/GB2020/051497 WO2020254828A1 (en) 2019-06-21 2020-06-19 Compositions

Publications (1)

Publication Number Publication Date
MX2021015762A true MX2021015762A (es) 2022-04-18

Family

ID=67060267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015762A MX2021015762A (es) 2019-06-21 2020-06-19 Composiciones.

Country Status (10)

Country Link
US (1) US20230143091A1 (es)
EP (1) EP3986570A1 (es)
JP (1) JP2022538089A (es)
KR (1) KR20220063148A (es)
CN (1) CN114555643A (es)
AU (1) AU2020295767A1 (es)
CA (1) CA3144200A1 (es)
IL (1) IL289125A (es)
MX (1) MX2021015762A (es)
WO (1) WO2020254828A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016156466A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
MX2021015763A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
WO2023227641A1 (en) * 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
ATE351911T1 (de) 2000-12-13 2007-02-15 Unilever Nv Verfahren zur herstellung von heterologen proteinen in fungi
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
CN1809383A (zh) * 2003-04-11 2006-07-26 免疫医疗公司 重组il－9抗体及其用途
EP2365000A3 (en) 2005-05-18 2013-01-16 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
US8940303B2 (en) 2010-01-28 2015-01-27 Glaxo Group Limited CD127 binding proteins
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
AU2014214850C1 (en) * 2013-02-06 2018-12-06 Celgene Corporation Modified T lymphocytes having improved specificity
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
EP3277719B1 (en) 2015-03-31 2022-03-16 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2016156466A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
CA3066054A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor

Also Published As

Publication number Publication date
WO2020254828A1 (en) 2020-12-24
CA3144200A1 (en) 2020-12-24
US20230143091A1 (en) 2023-05-11
KR20220063148A (ko) 2022-05-17
IL289125A (en) 2022-02-01
EP3986570A1 (en) 2022-04-27
CN114555643A (zh) 2022-05-27
JP2022538089A (ja) 2022-08-31
AU2020295767A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
MX2021015762A (es) Composiciones.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2020008542A (es) Composiciones y métodos para el suministro de proteínas membranales.
WO2019020602A3 (en) LUMINOPHORE AND COMPOSITION
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
ZA202106602B (en) Claudin 6 antibodies and uses thereof
WO2020123773A3 (en) Anellosomes for delivering secreted therapeutic modalities
WO2020123816A3 (en) Anellosomes and methods of use
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
MX2021007914A (es) Composiciones curables que comprenden poliolefinas insaturadas.
MX2019009759A (es) Composiciones de peptido estables.
MX2021003035A (es) Composiciones de alimento animal y usos de las mismas.
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
EP4043550A4 (en) COMPOSITION FOR INCREASE STEM CELL CAPABILITY AND THEREOF USE
EP3996735A4 (en) COMPOSITIONS AND METHODS FOR BLOCKING AND BINDING CXCR4 TO MODULATE CELLULAR FUNCTION
EP3890769A4 (en) COMPOSITIONS DERIVED FROM MODIFIED FLAGELLIN AND USES
EP3858868A4 (en) POLYPEPTIDE COMPOSITION
GB201909298D0 (en) Novel compositions and uses thereof
EP3821003A4 (en) COMPOSITIONS CONTAINING NON-STANDARD AMINO ACIDS AND USES THEREOF
EP3818245A4 (en) CEMENT COMPOSITIONS AND PROCESSES
MX2019014192A (es) Inhibidor de inmunosupresion asociado al cancer.
MX2023009567A (es) Formulaciones de polipeptidos de union a dr5.
MX2021015473A (es) Nuevo anticuerpo específico para cthrc1 y su uso.
ZA202005050B (en) Polypeptide, compositions and uses thereof